Janus Henderson Global Life Sciences benefits from an exceptional lead manager, strong support resources, and a consistently applied robust investment process with prudent risk management, underpinning its Above Average People and Process Pillar ratings.
Janus Henderson Global Life Sciences Fund Class S JFNSX
- NAV / 1-Day Return $84.63 / −1.34 %
- Fund Size $5.8B
- Adjusted Expense Ratio 1.190%
- Net Expense Ratio 1.180%
- Fee Level: Distribution Above Average
- Share Class Type No Load
- Morningstar Category Health
- Equity Style Box (Funds) Large Blend
- Minimum Initial Investment $2,500
- Investment Status Open
- TTM Yield 0.21%
- Turnover Ratio 30%
Morningstar’s Analysis JFNSX
Will JFNSX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 42.2
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 9.05 | 545M | Healthcare |
Johnson & Johnson | 7.48 | 450M | Healthcare |
AbbVie Inc | 4.63 | 279M | Healthcare |
UnitedHealth Group Inc | 4.33 | 261M | Healthcare |
AstraZeneca PLC | 3.50 | 211M | Healthcare |
Thermo Fisher Scientific Inc | 2.92 | 176M | Healthcare |
Novartis AG ADR | 2.78 | 167M | Healthcare |
Roche Holding AG 0% | 2.63 | 159M | Corporate |
argenx SE ADR | 2.55 | 154M | Healthcare |
Abbott Laboratories | 2.36 | 142M | Healthcare |